Sumitomo Pharma Co. Ltd.

Company Overview

Sumitomo Dainippon Pharma Co. Ltd. is a pharmaceutical company that operates globally under the slogan “innovation today, healthier tomorrow.

Sumitomo Dainippon Pharma engages in the development of therapeutic drugs for schizophrenia and Parkinson’s disease in the areas of neurology and psychiatry. On July 31, 2019, Sumitomo Dainippon Pharma launched Lurasidone hydrochloride for the treatment of bipolar depression and schizophrenia in Japan. The company’s therapeutic products include calcium chain blocker (CCB), ACE and angiotensin II receptor blocker (ARB) in the areas of diabetes and cardiovascular diseases.

Sumitomo Dainippon Pharma also contributes to medical care in other therapeutic fields, such as oncology, cell therapy, regenerative medicine, hematologic disorders, liver diseases and rare diseases. The major products in the areas of pharmaceuticals are Lonasen, Trulicity, Trerief, Replagal, AmBisome Remitch and EquMet.

The company’s animal healthcare products business is directed by DS Pharma Animal Health Co. Ltd., Sumitomo Dainippon Pharma’s subsidiary. Its major products are veterinary medicines and different products for companion animals, primarily cats and dogs; as well as for domesticated animals (e.g., horses, swine, cows, poultry, steeds, aquaculture fish).

Financial Highlights (FY 2024)

Company's Business Segments

• Pharmaceuticals : It offers pharmaceuticals for medical treatment.